http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2015, Vol. 24 ›› Issue (8): 552-556.DOI: 10.5246/jcps.2015.08.070

• Drug administration column • Previous Articles     Next Articles

Stakeholder analysis of clinical trials in China: a structural equation model

Xiaoyuan Zheng1, Linguang Zhou2, Bo Gao3, Song Yang1, Bin Jiang1*   

  1. 1. Department of Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
    2. Department of Pharmacy, Peking University International Hospital, Beijing 102206, China
    3. Department of Pharmacy, Peking University First Hospital, Beijing 100034, China
  • Received:2015-04-23 Revised:2015-05-10 Online:2015-08-22 Published:2015-05-25
  • Contact: Tel.: 13601100121, E-mail: binjiang@sina.com
  • Supported by:
    National Social Science Fund (Grant No. 13BGL141).

Abstract:

Stakeholder analysis was conducted to define stakeholders and their role in clinical trials; a conceptual model and hypotheses regarding the relationship of each stakeholder were then constructed based on pharmaceutical regulations in China and interviews with experts; Amos 17.0 was utilized to test the model and path analysis. We found that government and hospital are the most powerful stakeholders, while the public and sponsor have little impact on clinical trials. Further measures should be taken by sponsors to promote the development of clinical trials, and the public should be more involved in clinical research.

Key words: Clinical trial, Stakeholder analysis, Structural equation model

CLC Number: 

Supporting: